|
π¦
|
T cell anergy and costimulation
L. Appleman,
V. Boussiotis
|
8 |
2003 |
8
π¦
|
|
π
|
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
19 auth.
T. Choueiri,
S. Jacobus,
J. Bellmunt,
A. Qu,
L. Appleman,
C. Tretter,
G. Bubley,
E. Stack,
S. Signoretti,
Meghara Walsh,
...
G. Steele,
M. Hirsch,
C. Sweeney,
M. Taplin,
A. Kibel,
K. Krajewski,
P. Kantoff,
R. Ross,
J. Rosenberg
|
7 |
2014 |
7
π
|
|
π
|
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
24 auth.
T. Choueiri,
M. Fishman,
B. Escudier,
D. McDermott,
C. Drake,
H. Kluger,
W. Stadler,
J. PΓ©rez-Gracia,
D. McNeel,
B. Curti,
...
M. Harrison,
E. Plimack,
L. Appleman,
L. Fong,
L. Albiges,
L. Cohen,
Tina C. Young,
S. Chasalow,
P. Ross-Macdonald,
S. Srivastava,
M. Jure-Kunkel,
J. Kurland,
J. Simon,
M. Sznol
|
7 |
2016 |
7
π
|
|
π¦
|
CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression1
L. Appleman,
A. Berezovskaya,
Isabelle Grass,
V. Boussiotis
|
7 |
2000 |
7
π¦
|
|
π¦
|
CD28 Costimulation Mediates Down-Regulation of p27kip1 and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells1
L. Appleman,
A. V. van Puijenbroek,
Kirstin Shu,
L. Nadler,
V. Boussiotis
|
7 |
2002 |
7
π¦
|
|
π
|
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
21 auth.
A. Patnaik,
L. Appleman,
A. Tolcher,
K. Papadopoulos,
M. Beeram,
D. Rasco,
G. Weiss,
J. Sachdev,
M. Chadha,
Monica Fulk,
...
S. Ejadi,
J. Mountz,
M. Lotze,
F. Toledo,
E. Chu,
M. Jeffers,
C. PeΓ±a,
C. Xia,
S. Reif,
I. Genvresse,
R. Ramanathan
|
7 |
2016 |
7
π
|
|
π
|
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
14 auth.
J. Eder,
G. Shapiro,
L. Appleman,
A. Zhu,
D. Miles,
H. Keer,
B. Cancilla,
Felix Chu,
S. Hitchcock-bryan,
L. Sherman,
...
S. McCallum,
E. Heath,
S. Boerner,
P. LoRusso
|
7 |
2010 |
7
π
|
|
π
|
Inhibition of hypoxia-inducible factor-2Ξ± in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
12 auth.
T. Choueiri,
T. Bauer,
K. Papadopoulos,
E. Plimack,
J. Merchan,
D. McDermott,
...
M. Michaelson,
L. Appleman,
S. Thamake,
R. Perini,
N. Zojwalla,
E. Jonasch
|
7 |
2021 |
7
π
|
|
π
|
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
15 auth.
V. Koshkin,
P. Barata,
Tian Zhang,
D. George,
M. Atkins,
W. Kelly,
N. Vogelzang,
S. Pal,
J. Hsu,
L. Appleman,
...
M. Ornstein,
T. Gilligan,
P. Grivas,
Jorge A. Garcia,
B. Rini
|
7 |
2018 |
7
π
|
|
π
|
The High-Dose Aldesleukin βSelectβ Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
27 auth.
D. McDermott,
Su-Chun Cheng,
S. Signoretti,
K. Margolin,
Joseph I. Clark,
J. Sosman,
J. Dutcher,
T. Logan,
B. Curti,
M. Ernstoff,
L. Appleman,
M. Wong,
N. Khushalani,
L. Oleksowicz,
U. Vaishampayan,
...
J. Mier,
D. Panka,
R. Bhatt,
A. Bailey,
B. Leibovich,
E. Kwon,
F. Kabbinavar,
A. Belldegrun,
R. Figlin,
A. Pantuck,
M. Regan,
M. Atkins
|
7 |
2014 |
7
π
|
|
π
|
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
17 auth.
B. Escudier,
T. Powles,
R. Motzer,
T. Olencki,
O. ArΓ©n Frontera,
S. Oudard,
F. Rolland,
P. Tomczak,
D. Castellano,
L. Appleman,
...
H. Drabkin,
D. Vaena,
Steven Milwee,
J. Youkstetter,
J. Lougheed,
S. Bracarda,
T. Choueiri
|
6 |
2018 |
6
π
|
